The Department of Pediatrics is pleased to announce the appointment of Dr. Lisa Giulino-Roth to Professor of Pediatrics in Medicine, and Professor of Pathology and Laboratory Medicine in the Division of Pediatric Hematology/Oncology, effective December 1, 2024. Dr. Roth obtained her medical degree at New York University School of Medicine in 2005. She completed residency training in Pediatrics at Weill Cornell Medicine NewYork-Presbyterian, followed by a fellowship in Pediatric Hematology and Oncology in the joint Weill Cornell Medicine Memorial Sloan Kettering Cancer Center program, followed by an additional year, continuing her research in the laboratory of Dr. Ethel Cesarman, tenured Professor of Pathology. Dr. Roth joined Weill Cornell Medicine (WCM) as Assistant Professor in 2012 and was promoted to Associate Professor of Pediatrics in 2019. She is a physician-scientist with internationally recognized expertise in B-cell lymphoma. Her basic research work has identified targetable genomic changes in lymphoma. She has also done mechanistic work on the role of EZH2 inhibition in tumorigenesis, and on mechanisms of latency in EBV-positive lymphomas. For each of these areas, she has published her findings in high-impact specialty hematology and oncology journals as the corresponding lead or senior author. In addition, Dr. Roth has conducted several large-scale clinical trials in lymphoma in both children and adults. Dr. Roth serves as study chair for two clinical trials within the Children’s Oncology Group: One is a phase II trial evaluating pembrolizumab in pediatric Hodgkin lymphoma and the other is a phase III trial evaluating nivolumab in primary mediastinal B-cell lymphoma. Dr. Roth has received multiple NIH awards to fund her research starting with a K08 Award, which she was able to successfully transition to an R37 MERIT Award. She has also received the American Society of Clinical Investigation Young Physician-Scientist Award, the American Society of Hematology Scholar Award, the Hyundai Hope on Wheels Young Investigator Award, and the Scholar Hope Award. She has published over 50 research articles, 16 as the first and 5 as the last author. She has further published 19 review articles and 9 book chapters. She has served as an ad hoc reviewer for several high-impact journals. She also serves on the NIH Immuno-Oncology Research NIH 2022-OTC-D08 study section. Dr. Roth has been invited to lecture nationally and internationally on her research. She is clearly recognized as a leader in the field on non-Hodgkin Lymphoma. We are delighted about Dr. Roth’s accomplishments and promotion to Professor and look forward to her future achievements at Weill Cornell Medicine. |